What is Chai Discovery?

Chai Discovery is a company that provides generative AI for antibody design. The article does not provide further details about the company.

What is the financial value of the deal?

The article does not disclose financial terms of the partnership.

The article does not specify particular antibodies or therapeutic areas; it mentions the collaboration is across BMS's portfolio.

Bristol Myers Squibb is partnering with Chai Discovery to use generative AI for antibody design across its portfolio.
This highlights AI's growing role in pharmaceutical R&D.
Financial details are undisclosed.

What happened
Bristol Myers Squibb (BMS) is partnering with Chai Discovery to use its generative AI for antibody design across BMS's portfolio. The collaboration is announced, though specific financial terms are not disclosed.
Why it matters
This marks a significant adoption of generative AI in drug discovery, potentially accelerating the design of antibodies, which are key components in many modern therapies. It underscores the growing role of AI in pharmaceutical R&D.
What to watch
How this partnership may influence BMS's pipeline and whether it signals broader industry adoption of AI-driven drug design. The specific antibodies or therapeutic areas targeted are not yet specified.

Summaries like this, in your inbox every morning.

What is Chai Discovery?: Chai Discovery is a company that provides generative AI for antibody design. The article does not provide further details about the company.
What is the financial value of the deal?: The article does not disclose financial terms of the partnership.
Which specific antibodies or disease targets are involved?: The article does not specify particular antibodies or therapeutic areas; it mentions the collaboration is across BMS's portfolio.